MacroGenics (MGNX) has wrapped up FY 2025 with fourth quarter revenue of US$41.2 million and a basic EPS loss of US$0.22, as the market weighs these results against a share price of US$3.43. The company has seen revenue move from US$110.7 million in Q3 2024 to US$72.8 million in Q3 2025, while basic EPS shifted from a profit of US$0.90 to a profit of US$0.27 over the same period, creating a mixed picture on topline scale and per share results. Overall, margins remain under pressure, which keeps profitability and cash burn front and center for investors parsing this update.

See our full analysis for MacroGenics.

With the headline numbers on the table, the next step is to see how these results line up with the dominant bull and bear stories around MacroGenics and where the data pushes back on those narratives.

See what the community is saying about MacroGenics

Losses Still Large At US$74.6 Million Over The Year

• On a trailing twelve month basis to Q4 2025, MacroGenics booked a net loss of US$74.6 million on US$149.5 million of revenue, with full year basic EPS at a loss of US$1.18.
• Critics highlight that analysts expect earnings to decline about 17.4% per year over the next three years, and the current loss profile keeps that bearish concern in play:
  • The company has been unprofitable across the last twelve months, consistent with the view that near term profitability is unlikely.
  • At the same time, bears focus on rising research and development spend and ongoing losses as signs that funding needs could stay significant if revenue continues to trend down.

MacroGenics' current loss run rate and forecasts for further earnings declines are exactly what skeptics are focused on, and they outline how this could limit the long term payoff for shareholders. 🐻 MacroGenics Bear Case

Revenue Swings And LTM Decline To US$149.5 Million

• Trailing twelve month revenue has moved to US$149.5 million by Q4 2025 compared with US$165.5 million at Q2 2025 and US$149.96 million at Q4 2024, while quarterly revenue ranged from US$13.2 million to US$110.7 million over the last six quarters.
• Supporters argue that this choppy revenue line sits beside a five year trend of losses narrowing about 25% per year, which they see as building a bullish case:
  • Revenue is expected to decline about 6.6% per year over the next three years, yet bulls point to past progress in reducing losses as evidence the cost base can be managed.
  • They also flag that new trials like LORIKEET and LINNET could, if successful, help make better use of this revenue base even if sales are not growing rapidly in the near term.

For investors who think the pipeline can eventually turn this uneven revenue into a more efficient business, the existing loss reduction trend is a key part of the bullish story. 🐂 MacroGenics Bull Case

P/S Of 1.5x Sits Well Below Biotech Peers

• MacroGenics trades on a P/S of about 1.5x, compared with 12.3x for the US biotech industry and 19.2x for its peer group, while the current share price is US$3.43 and analysts’ consensus price target is US$3.60.
• Consensus narrative notes that this low sales multiple and the long term reduction in losses can be read together with the cautious revenue outlook, rather than in isolation:
  • Revenue is expected to decline around 20% per year over the next three years, which helps explain why the market assigns a much lower multiple than industry averages.
  • At the same time, the five year track record of shrinking losses and a consensus target slightly above the current price show that some analysts still see room for improvement if the pipeline delivers.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for MacroGenics on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If this mix of risks and potential has you on the fence, it is worth checking the numbers yourself and forming your own stance quickly. You can start by weighing up the 3 important warning signs tied to the latest data points and seeing how they align with your risk tolerance.

See What Else Is Out There

MacroGenics is still booking sizable losses alongside uneven revenue and a relatively low P/S multiple, which keeps profitability risk and downside uncertainty in clear view for shareholders.

If you want ideas that may lean more toward resilience than uncertainty, take a few minutes to scan our 68 resilient stocks with low risk scores that filter for companies with risk profiles that could better match a cautious approach.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.